Company Information

  

Address: 435 DEVON PARK DRIVE,
SUITE 715 
City: WAYNE 
State: PA 
Zip Code: 19087 
Telephone: 610-254-4201 

Description of Business

Primary SIC Code: 2836
(As filed with the SEC)  

We are a clinical stage biopharmaceutical company with an emphasis on identifying the genetic drivers of disease and applying this understanding to the pursuit of differentiated novel therapies for pediatric onset, life-altering diseases, including rare and orphan diseases. Our lead program, AEVI-001, is an oral, non-stimulant glutamatergic neuromodulator which is currently being studied in our Phase 2/3 SAGA trial, for a genetically-defined subset of adolescent Attention Deficit Hyperactivity Disorder, ADHD, patients with specific mutations in their mGluR gene network, which we refer to as mGluR+ ADHD. We expect to release top line results for this trial in the first quarter of 2017. We are also studying AEVI-001 in patients with 22q Deletion Syndrome, or 22q DS, a rare genetic pediatric disorder, and expect data from this signal finding trial in 2017.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-1.01NAN/E
03/2017-1.14NAN/E
12/2016-1.19NAN/E
09/2016-1.12NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.19Total Liab/Total Assets0.14
Net Inc/Total Assets-1.03Total Liab/Inv Cap0.16
Net Inc/Inv Cap-1.20Total Liab/Comm Equity0.03
Pretax Inc/Net SalesNAInterest Coverage Ratio-1744.33
Net Inc/Net SalesNACurr Debt/EquityNA
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio7.20
Inventory TurnoverNACurrent Ratio7.20
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) NA NA NA NA
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 2.37 2.99 3.35 3.04
Operating Income -8.04 -10.94 -8.48 -10.57
Interest Exp NA NA 0.01 0.01
Pretax Income -8.03 -10.92 -8.48 -10.56
Other Income NA NA 0.01 NA
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -8.03 -10.92 -8.48 -10.57

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 21.36 29.20 39.84 47.26
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA NA
Total Current Assets 22.43 30.19 40.17 47.85
Net Property, Plant & Equipment 0.30 0.34 0.38 0.45
Total Assets 22.74 30.53 40.56 48.33
Liabilities        
Accounts Payable 4.92 5.45 5.58 5.50
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 4.92 5.45 5.58 5.50
Long-Term Debt NA NA NA NA
Total Liabilities 4.92 5.45 5.58 5.50
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 0.00 0.00 0.00 0.00
Retained Earnings -199.21 -191.18 -180.03 -171.55
Treasury Stock NA NA NA NA
Total Stockholders' Equity 17.82 25.08 34.98 42.83
Total Liabilities and Stockholders' Equity 22.74 30.53 40.56 48.33

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -7.85 -10.65 -7.48 -6.33
Net Cash Provided by Investing Activities 0.00 0.00 0.04 -0.07
Net Cash Provided by Financing Activities 0.00 0.02 0.02 -0.03

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20120.00-15.07--
12/20130.00-17.13--
12/20140.00-18.43--
12/20150.00-37.99--
12/20160.00-41.90-1.19
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/17837,83321.11




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.